On August 30, 2019 Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, reported that Randall E. Woods, president and chief executive officer, will present a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 3:00 p.m. EDT in New York, NY (Press release, Sophiris Bio, AUG 30, 2019, https://www.prnewswire.com/news-releases/sophiris-bio-to-present-at-the-hc-wainwright-21st-annual-global-investment-conference-300909439.html [SID1234539156]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will be webcast live and can be accessed through the Investor Relations page at www.sophirisbio.com. A replay of the presentation will be available on the Company’s website for 90 days.